相关实验视频

Updated: May 13, 2026

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein

Published on: January 2, 2015

通过针对蛋白质分解的嵌合体选择性降解高酸化陶,改善了阿尔茨海默病模型小鼠的认知功能

Dongping Yao¹, Ting Li², Lu Yu¹

¹State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.

Frontiers in pharmacology

|June 26, 2024

概括

在阿尔茨海默氏症模型中,一种新型的PROTAC分子C8有效降解有害的陶蛋白. 这种有针对性的方法有望改善认知功能,并提供一种潜在的更安全的治疗策略.

科学领域:

神经科学是一个神经科学.
生物化学生物化学
药理学药理学是指药理学的学科.

背景情况:

阿尔茨海默病 (AD) 是神经退行的主要原因,其特征是神经元功能障碍和突触损伤.
过酸化的蛋白是一种关键的病理标志,与AD进展有关.
向蛋白解酶的仿真体 (PROTACs) 是一种针对向蛋白质降解的新疗法.

研究的目的:

设计和合成小分子PROTACs用于阿尔茨海默病中蛋白的有针对性淘汰.
为了评估一个PROTAC化合物 (C8) 在降低总和化水平方面的有效性.
评估C8在改善AD模型中的认知缺陷方面的治疗潜力.

主要方法:

设计和合成针对蛋白的小分子PROTACs.
在细胞系 (HEK293-htau) 和超表达的小鼠中使用西部斑分析验证tau降解.
使用行为测试 (新型物体识别和莫里斯水迷宫) 评估 htau过度表达的小鼠的认知功能.

主要成果:

化合物C8在体外和体内成功降低了总和酸化的水平.
西方斑点分析证实,C8介导的降解通过随时依赖的ubiquitin-proteasome系统发生.
C8治疗显著改善了 htau过度表达的小鼠的认知表现,行为测试结果证明了这一点.

结论:

小分子PROTAC C8表明酸化的强烈降解,这是阿尔茨海默病的关键标.
使用PROTACs的向降解为AD提供了一个特定的,与传统治疗相比,可能更有效的治疗策略.
化合物C8作为阿尔茨海默病的新型治疗候选人具有前景,需要进一步调查.

关键词:

阿尔茨海默氏症是阿尔茨海默氏症的一种疾病.这就是 PROTACs.过酸化的酸.有针对性的蛋白质降解降解.无处不在的蛋白质酶体系统.

更多相关视频

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Using Enzyme-based Biosensors to Measure Tonic and Phasic Glutamate in Alzheimer's Mouse Models

Published on: May 3, 2017

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

An In Vitro Model for Studying Tau Aggregation Using Lentiviral-mediated Transduction of Human Neurons

Published on: May 23, 2019

相关概念视频

Alzheimer's Disease: Treatment

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...

Alzheimer Disease ll: Pathophysiology

Alzheimer Disease ll: Pathophysiology

Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...